Single-agent Aredia for relapsed/refractory multiple myeloma.

被引：0
|
作者：
Berenson, JR
Webb, IJ
Anderson, K
Schlossman, R
Vescio, R
Doss, D
Goon, B
Swift, R
VonTeichert, J
Kowalski, M
Seaman, J
机构：
[1] W LA VA Med Ctr, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Novartis Pharmaceut Corp, Clin Res, E Hanover, NJ USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4601
引用
收藏
页码：307B / 307B
页数：1
相关论文
共 50 条
  • [21] Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study
    Cejalvo, Maria J.
    Legarda, Mario
    Abella, Eugenia
    Cabezudo, Elena
    Encinas, Cristina
    Garcia-Feria, Ana
    Gironella, Mercedes
    Inigo, Belen
    Martin, Jesus
    Ribas, Paz
    Angeles Ruiz, Ma
    Gonzalez, Yolanda
    Vicuna, Isabel
    Ramirez, Angel
    Fernandez, Pascual
    de la Rubia, Javier
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (05) : E289 - E292
  • [22] Overview and Management of Cardiac and Pulmonary Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Wang, Michael
    Cheng, Jie
    ONCOLOGY-NEW YORK, 2013, 27 : 24 - 30
  • [23] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
    Siegel, D. S.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lonial, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 20 - 20
  • [24] Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
    Harvey, R. Donald
    Lonial, Sagar
    Patel, Priti
    McCulloch, Leanne
    Niesvizky, Ruben
    Kaufman, Jonathan L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
    Richter, Joshua Ryan
    Landgren, Carl Ola
    Kauh, John S.
    Back, Jonathan
    Salhi, Yacine
    Reddy, Venkateshwar
    Bayever, Eliel
    Berdeja, Jesus G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
    Richter, Joshua Ryan
    Wermke, Martin
    Kauh, John S.
    Back, Jonathan
    Salhi, Yacine
    Reddy, Venkateshwar
    Bayever, Eliel
    Landgren, Carl Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [27] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Clinical synergism of Bortezomib and chemotherapy in relapsed and refractory multiple myeloma.
    Mazumder, A
    Chauvin, E
    Curran, K
    Disperati, P
    Jagannath, S
    BLOOD, 2003, 102 (11) : 390B - 390B
  • [29] Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lotfi
    Gasparetto, Cristina
    Amiot, Martine
    Moreau, Philippe
    Diehl, Susan
    Alzate, Stefanie
    Ross, Jeremy A.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh K.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [30] Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Lokhorst, Henk M.
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte Rose
    Minnema, Monique
    Lassen, Ulrik Niels
    Ahmadi, Tahamtan
    Yeh, Howard
    Guckert, Mary
    Brun, Nikolai C.
    Lisby, Steen
    Basse, Linda
    Palumbo, Antonio
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345